[Breast-preserving treatment of breast cancer and peroperative curietherapy].
From May 1988 to December 1990, 35 patients benefitted from a breast-conserving treatment (tumor resection with at least 1 cm of free margin, axillary dissection and peroperative brachytherapy). The iridium sources were introduced 24 h later, delivering between 15 to 17.5 Gy. Three weeks later an additional course of external radiation delivered a dose of 50 Gy in 5 weeks to the whole breast. In this series, only very early breast lesions were included and no patient received additional chemotherapy. Due to the short period of observation, we only report on the acute side effects even if until now we have not seen any case of tumor relapse. We did not observe any major complications after this combined approach: only three patients developed a local infection requiring antibiotics. Esthetic evaluation is quite encouraging with all women showing good and excellent results from the physician's and patient's points of view. This approach seems to be quite interesting cosmetically as it allows to correct the breast shape while preserving an adequate position of the implant and so preserving a good oncological approach.
Nogaret
J M
JM
Services de Chirurgie, Institut Jules Bordet, Bruxelles.
Lorent
I
I
Batrouni
R
R
Lacotte
B
B
Coibion
M
M
Hertens
D
D
Mattheiem
W
W
Gasperin
P
P
Van Houtte
P
P
D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000379:methods*; D001943:Breast Neoplasms / Q000532:radiotherapy / Q000601:surgery*; D002277:Carcinoma / Q000532:radiotherapy / Q000601:surgery*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007495:Iridium; D015412:Mastectomy, Segmental; D008875:Middle Aged; D011867:Radioisotope Teletherapy / Q000379:methods*
D003037:Cobalt Radioisotopes; D007495:Iridium
Traitement conservateur du cancer du sein et curiethérapie peropératoire.